PRNewswire
- Simcere Pharmaceutical schließt eine Forschungskooperationsvereinbarung mit Stanford Medicine zur Entwicklung innovativer Therapien für Patienten mit idiopathischer LungenfibroseSHANGHAI, 13. Juni 2026 /PRNewswire/ — Am 29. Mai 2026 (Pacific Time) schloss die Simcere Pharmaceutical Group Limited (2096.HK) eine… Read more »
Kos Biotechnology Partners Announces Third Closing of Global Life Sciences Fund at $123 MillionNEW YORK and ATHENS, Greece, June 13, 2026 /PRNewswire/ — Kos Biotechnology Partners (“Kos”), a global life sciences investment firm… Read more »- MGI Tech Showcases Expanding Genomics Ecosystem at ESHG 2026 with New IVD Partnering Program and OEM CollaborationsGOTHENBURG, Sweden, June 13, 2026 /PRNewswire/ — MGI Tech Co., Ltd. (MGI), a company committed to developing core tools and… Read more »
Lilly to present initial clinical data for first-in-class type II JAK2 inhibitor in patients with previously treated myelofibrosis at the 2026 EHA Annual MeetingINDIANAPOLIS, June 13, 2026 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today announced new data from the Phase 1… Read more »
New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myelomaTALVEY® plus DARZALEX FASPRO® with or without pomalidomide showed progression-free survival of up to 81% and overall survival of up… Read more »
Angel Yeast Releases 2025 Sustainability Report as Company Marks 40th AnniversarySHANGHAI, June 12, 2026 /PRNewswire/ — Angel Yeast (SSE: 600298), one of the world’s leading yeast manufacturers, recently marked its… Read more »- Simcere Pharmaceutical sluit samenwerkingsovereenkomst voor onderzoek met Stanford Medicine voor de ontwikkeling van innovatieve behandelingen voor patiënten met idiopathische pulmonale fibroseSHANGHAI, 13 juni 2026 /PRNewswire/ — Op 29 mei 2026 (Pacific Time) heeft Simcere Pharmaceutical Group Limited (2096.HK) een samenwerkingsovereenkomst… Read more »
- Simcere Pharmaceutical conclut un accord de collaboration en matière de recherche avec Stanford Medicine en vue de développer des traitements innovants pour les patients atteints de fibrose pulmonaire idiopathiqueSHANGHAI, 13 juin 2026 /PRNewswire/ — Le 29 mai 2026, heure du Pacifique, Simcere Pharmaceutical Group Limited (2096.HK) a passé… Read more »
Atossa Therapeutics Announces Closing of Registered Direct Offering of up to $16.5 Million in Gross Proceeds$4.5 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon exercise in full of… Read more »
Volta Labs intègre l'ensemble de la gamme de capture hybride de Twist à Callisto™ avec le lancement de Twist Fast HybL’application Twist Fast Hyb vient s’ajouter à l’application Twist Standard Hyb v2 sur Callisto, offrant aux laboratoires une solution entièrement… Read more »
Volta Labs erweitert das Twist-Hybrid-Capture-Portfolio für Callisto™ mit der Einführung von Twist Fast HybDie Twist Fast Hyb App ergänzt die Standard Hyb v2 App von Twist auf Callisto und bietet Labors einen vollständig… Read more »
Volta Labs trae la cartera completa de captura híbrida Twist a Callisto™ con el lanzamiento de Twist Fast HybLa aplicación Twist Fast Hyb se une a la aplicación Standard Hyb v2 de Twist en Callisto, proporcionando a los… Read more »
BRC Therapeutics Appoints Ron Eastman to Board of DirectorsVeteran Pharma Executive and Healthcare Investor Brings More Than 40 Years of Drug Development, Operations and Investment Experience MONTEREY, Calif.,… Read more »
In Vitro Toxicology Testing Market worth $20.97 billion by 2031 | MarketsandMarkets™DELRAY BEACH, Fla., June 12, 2026 /PRNewswire/ — According to MarketsandMarkets™, the In Vitro Toxicology Testing Market is projected to… Read more »
Volta Labs Brings the Complete Twist Hybrid Capture Portfolio to Callisto™ with Launch of Twist Fast HybThe Twist Fast Hyb App joins Twist’s Standard Hyb v2 App on Callisto, giving labs a fully walk-away path to… Read more »- Promising First-in-Patient Results for ACOU085 (INN: Bimokalner) in Cisplatin-Induced OtotoxicityTÜBINGEN, Germany, June 12, 2026 /PRNewswire/ — Acousia Therapeutics GmbH, a clinical-stage biotechnology company pioneering treatments for acute and chronic… Read more »
O'Shaughnessy Ventures Backs Bioengineer Working to Cure Her Own DiseaseHéloïse Hoffmann awarded an O’Shaughnessy Fellowship to develop a gene therapy for the rare muscle disease she lives with GREENWICH,… Read more »
GELITA Unveils Next-Generation Excipient Innovations at BIO International 2026 in San DiegoEBERBACH, Germany and SIOUX CITY, Iowa, June 12, 2026 /PRNewswire/ — GELITA, a global leader in collagen protein solutions, will… Read more »
Hartwig Medical Foundation and Ultima Genomics Expand Collaboration to Advance Whole-Genome Sequencing in Oncology CareHartwig to adopt Ultima Genomics’ UG200 sequencing system to accelerate implementation of whole-genome-based clinical genomics workflows on Solaris 2.0 technology… Read more »
Willow Laboratories Welcomes Dr. Jill Biden, Ken Buck, and Said Hilal to Willow's Board of DirectorsDistinguished leaders in education, healthcare innovation and public service join Willow to help advance its mission of improving healthspan and… Read more »